The clinical significance ofBRAFandNRASmutations in a clinic-based metastatic melanoma cohort
British Journal of Dermatology2013Vol. 169(5), pp. 1049–1055
Citations Over TimeTop 10% of 2013 papers
Henrik Ekedahl, Helena Cirenajwis, Katja Harbst, Ana Carneiro, K. Nielsen, Håkan Olsson, Lotta Lundgren, Christian Ingvar, Göran Jönsson
Abstract
We were able to confirm the effect of BRAF inhibitor treatment in a single clinical institution. The results suggest further that BRAF mutation is a weak prognostic factor but a strong predictive factor and that BRAF-mutant melanoma might constitute one or more distinct subtypes of the disease with certain aetiology and clinical outcome.
Related Papers
- → Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma(2011)238 cited
- → Detection of KRAS, NRAS and BRAF by mass spectrometry - a sensitive, reliable, fast and cost-effective technique(2015)36 cited
- → Molecular testing for BRAF V600 mutations in the BRIM-2 trial of the BRAF inhibitor vemurafenib in metastatic melanoma.(2011)5 cited
- → Detection of Rare Mutations by Routine Analysis of KRAS, NRAS, and BRAF Oncogenes(2017)1 cited
- → Clinical characteristics and outcomes associated with molecular status and treatment with vemurafenib in metastatic melanoma (MM) in a real-world setting: Comparison of four groups.(2018)